We are pleased to bring answers to operational, policy, financial, systems and compliance questions from the AMP Final Rule.
New York, New York (PRWEB) April 14, 2014
The much awaited AMP final rule revises requirements for Medicaid reimbursement for covered outpatient drugs to implement provisions of the Affordable Care Act (ACA). This summit brings together GP and MDRP experts to identify significant administrative and compliance challenges faced by the industry and answer questions covering operational, policy, financial, systems and compliance topics.
The timing of this summit is based around the anticipated publication of the AMP Final Rule in May 2014 and to allow the speaking faculty time to determine the unexpected parts of the rule and be able to provide practical recommendations.
"We are pleased to bring answers to operational, policy, financial, systems and compliance questions from the AMP Final Rule,” says Anne Reel, Executive Program Director.
The AMP Final Rule and 340B event is July 10-11, in Baltimore, Maryland.
Speaking faculty is made up of senior Medicaid, government programs and pricing experts representing: Pfizer, Genentech, Hospira, Johnson & Johnson, Daiichi Sankyo, Dendreon, Johnson & Johnson, Eli Lilly and Company, National Association of Chain Drug Stores (NACDS) and more.
About The Conference Forum:
The Conference Forum has a very specific focus – developing specialized events both public and private as well as research groups and advisory boards for professionals in the life science industry. We currently offer conferences for R&D leaders, Clinical Development professionals, young and established Biotech executives, and Drug Delivery specialists. Our mission is to create the best content in an ideal forum for the exchange of ideas among peers and networking for Pharmaceutical and Biotech professionals.